Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: NOV-002
Drug: Carboplatin

First Posted Date: 2006-06-28

Last Posted Date: 2015-03-10

Lead Sponsor: Cellectar Biosciences, Inc.

Target Recruit Count: 15

Registration Number: NCT00345540

Locations: 🇺🇸
Dana Farber Cancer/Partners Cancer Care, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Cetuximab
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-06-22

Last Posted Date: 2011-06-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 121

Registration Number: NCT00343291

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Phase 3

Active, not recruiting

Conditions: Medulloblastoma
Anaplastic Medulloblastoma
Supratentorial Embryonal Tumor, Not Otherwise Specified
Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Leucovorin Calcium
Drug: Thiotepa
Drug: Methotrexate
Drug: Vincristine Sulfate

First Posted Date: 2006-06-12

Last Posted Date: 2024-09-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 91

Registration Number: NCT00336024

Locations: 🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸
NYU Langone Hospital - Long Island, Mineola, New York, United States

and more 142 locations

Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Phase 3

Completed

Conditions: Intraocular Retinoblastoma

Interventions: Drug: liposomal vincristine sulfate
Drug: carboplatin
Drug: etoposide

First Posted Date: 2006-06-12

Last Posted Date: 2021-02-18

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 331

Registration Number: NCT00335738

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 53 locations

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Phase 2

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Childhood Renal Cell Carcinoma
Clear Cell Sarcoma of the Kidney
Papillary Renal Cell Carcinoma
Stage I Renal Cell Cancer
Stage II Renal Cell Cancer
Rhabdoid Tumor of the Kidney
Stage I Renal Wilms Tumor
Stage IV Renal Wilms Tumor
Stage II Renal Wilms Tumor

Interventions: Drug: Doxorubicin Hydrochloride
Procedure: Conventional Surgery
Drug: Irinotecan Hydrochloride
Biological: Dactinomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Carboplatin
Drug: Vincristine Sulfate
Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy

First Posted Date: 2006-06-12

Last Posted Date: 2017-07-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 291

Registration Number: NCT00335556

Locations: 🇺🇸
Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States

and more 184 locations

Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

First Posted Date: 2006-06-08

Last Posted Date: 2012-07-10

Lead Sponsor: Northwestern University

Target Recruit Count: 32

Registration Number: NCT00334763

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Evanston Northwestern Healthcare - Evanston Hospital, Evanston, Illinois, United States

and more 2 locations

Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients

Phase 1

Completed

Conditions: Endometrial Cancer

Interventions: Radiation: IMRT
Radiation: Intracavitary vaginal brachytherapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-06-07

Last Posted Date: 2015-10-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 65

Registration Number: NCT00334321

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2

Terminated

Conditions: Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Procedure: cytoreductive surgery

First Posted Date: 2006-05-31

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 7

Registration Number: NCT00331422

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Inoperable Non Small Cell Lung Cancer

Interventions: Drug: Premetrexed (Alimta)
Drug: Carboplatin

First Posted Date: 2006-05-25

Last Posted Date: 2016-12-02

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 18

Registration Number: NCT00330044

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Phase 2

Completed

Conditions: Extraocular Extension Melanoma
Iris Melanoma
Recurrent Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Metastatic Intraocular Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: sorafenib tosylate

First Posted Date: 2006-05-25

Last Posted Date: 2014-07-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00329641

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy